{"organizations": [], "uuid": "f6f3740d59f6f07333d99d2a73330c813215cd16", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180412.html", "section_title": "Archive News &amp; Video for Thursday, 12 Apr 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-mithra-pharmaceuticals-signs-princ/brief-mithra-pharmaceuticals-signs-principle-agreement-for-estelle-commercialization-in-canada-with-searchlight-pharma-idUSFWN1RP03Z", "country": "US", "domain_rank": 408, "title": "BRIEF-Mithra Pharmaceuticals Signs Principle Agreement For Estelle Commercialization In Canada With Searchlight Pharma", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.002, "site_type": "news", "published": "2018-04-12T13:49:00.000+03:00", "replies_count": 0, "uuid": "f6f3740d59f6f07333d99d2a73330c813215cd16"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-mithra-pharmaceuticals-signs-princ/brief-mithra-pharmaceuticals-signs-principle-agreement-for-estelle-commercialization-in-canada-with-searchlight-pharma-idUSFWN1RP03Z", "ord_in_thread": 0, "title": "BRIEF-Mithra Pharmaceuticals Signs Principle Agreement For Estelle Commercialization In Canada With Searchlight Pharma", "locations": [], "entities": {"persons": [{"name": "estelle commercializ", "sentiment": "negative"}], "locations": [{"name": "canada", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "gdynia newsroom", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 12 (Reuters) - MITHRA PHARMACEUTICALS SA:\n* SIGNS PRINCIPLE AGREEMENT FOR ESTELLE COMMERCIALIZATION IN CANADA WITH SEARCHLIGHT PHARMA\n* TOP LINE RESULTS FOR ESTELLE PHASE 3 TRIALS EXPECTED IN Q3 2018 AND Q1 2019\n* ELIGIBLE TO RECEIVE UP TO EUR 15 MILLION IN UPFRONT PAYMENTS AND SALES-RELATED REVENUES\n* TO MANUFACTURE ESTELLE FOR SEARCHLIGHT AND RECEIVE GUARANTEED ANNUAL RECURRING REVENUES\n* THE ANNUAL RECURRING REVENUES TO BE BASED ON MINIMUM ANNUAL QUANTITIES\n* AGREEMENT COULD ACHIEVE REVENUES OF AT LEAST EUR 50 MILLION FOR MITHRA Source text: bit.ly/2qoG2mt Further company coverage: (Gdynia Newsroom)\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.facebook.com/Reuters", "https://bit.ly/2qoG2mt", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://www.linkedin.com/company/10256858/", "https://instagram.com/reuters/"], "published": "2018-04-12T13:49:00.000+03:00", "crawled": "2018-04-13T17:45:43.006+03:00", "highlightTitle": ""}